.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Chubb
Moodys
Daiichi Sankyo
Novartis
UBS
Federal Trade Commission
Citi
Covington
Healthtrust

Generated: November 23, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,163,725

« Back to Dashboard

Which drugs does patent 8,163,725 protect, and when does it expire?


Patent 8,163,725 protects MIRVASO and is included in one NDA. There has been one Paragraph IV challenge on Mirvaso.

This patent has twenty-six patent family members in twenty-four countries.

Summary for Patent: 8,163,725

Title:Gel compositions and methods of use
Abstract: Improved topical gel compositions for the treatment of skin disorders are described. The gel compositions contain carbomer and methylparaben, and are substantially free of methylparaben crystalline particles after an extended period of storage.
Inventor(s): Buge; Jean-Christophe (Nice, FR), Nadau-Fourcade; Karine (Villeneuve-Loubet, FR), Meunier; Cyril (Mougins, FR)
Assignee: Galderma R&D SNC (Biot, FR)
Application Number:13/240,562
Patent Claim Types:
see list of patent claims
Composition; Compound; Formulation; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Galderma Labs Lp
MIRVASO
brimonidine tartrate
GEL;TOPICAL204708-001Aug 23, 2013RXYesYes► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,163,725

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,053,427Brimonidine gel composition► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,163,725

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina083651► Subscribe
Australia2011317554► Subscribe
Brazil112013009578► Subscribe
Canada2814952► Subscribe
China103298451► Subscribe
Cyprus1115683► Subscribe
Denmark2444068► Subscribe
European Patent Office2444068► Subscribe
European Patent Office2629757► Subscribe
Spain2498217► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Fuji
Farmers Insurance
Chinese Patent Office
Fish and Richardson
Baxter
McKinsey
Chubb
Teva
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot